Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Shift From Loss To Profit
yahoo.com
news
2022-10-18 11:37:12

With the business potentially at an important milestone, we thought we'd take a closer look at Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) future prospects. Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. The US$107m market-cap company posted a loss in its most recent financial year of US$77m and a latest trailing-twelve-month loss of US$102m leading to an even wider gap between loss and breakeven.
